Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing ≥ 10% epidermal growth factor receptor (EGFr)
Year: 2006
Type: conference-abstract
Source: Journal of Clinical Oncology
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: panitumumab, metastatic colorectal cancer, epidermal growth factor receptor, anti-EGFR monoclonal antibody, refractory disease, objective response rate, progression-free survival, treatment-related adverse events, skin toxicity, ocular toxicity, irinotecan, oxaliplatin, fluoropyrimidine, duration of response, survival
Open Access status: closed
OpenAlex ID: W3011109864
